Camille Ragin was named associate director of diversity, equity, and inclusion at Fox Chase Cancer Center.
Ashish K. Jha, dean of Brown University’s School of Public Health, will succeed Jeffrey Zients to serve as the White House coronavirus response coordinator, at the request of President Joe Biden.
Martin S. Tallman was named director of faculty mentorship and career development at Lurie Cancer Center, effective June 1. Tallman will focus on the management and development of treatments for patients with both acute and chronic leukemias.
Dorothy Graves named assistant vice president and associate director for administration at Sylvester
Dorothy Graves was named assistant vice president and associate director for administration of Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Davey Daniel was appointed chief medical officer of OneOncology on Feb. 7, succeeding Lee Schwartzberg, who will remain a senior advisor to the company.
The NCI-MATCH trial offers treatment opportunities for adult patients with relapsed, refractory cancers. A new treatment arm (Z1M) is evaluating the immunotherapy combination of relatlimab and nivolumab in patients whose tumors have mismatch repair deficiency and LAG-3 expression and have progressed after anti–PD-1/PD-L1 immunotherapy.
A study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumor-killing effects of cisplatin in animal models.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) conducted an extensive review of both peer-reviewed research studies and governmental public health data, looking at the so-called “intersectionality” of factors influencing health disparities to determine that sexual and racial minority status influences cancer screening behaviors and cancer risk.
Yale Cancer Center researchers have identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.
Scientists at Yale Cancer Center have discovered consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.
